All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Cost effectiveness of axicabtagene ciloleucel in R/R DLBCL
CAR T‐cell therapies have greatly improved clinical outcomes for patients with DLBCL who relapse after two prior therapies and, following the recent FDA approval of axicabtagene ciloleucel...
Visual abstract | Rehabilitation strategies for patients undergoing CAR T-cell therapy
A visual abstract summarizing rehabilitation needs associated with CAR T-cell therapies.
Are you a healthcare professional? What is your specialty?
Please select or type your specialty
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.